Publication
Real-world minimal residual disease assessment in multiple myeloma using a standardized flow cytometry approach: feasibility, clinical implications, and immune correlates from a single-center experience.
Cirino Botta, Andrea Rizzuto, Maria Speciale, Emilia Gigliotta, Anna Maria Corsale, Francesco Romano, Irene Mussotto, Cristina Aquilina, Andrea Romano, Marta Biondo, Elena Tofacchi, Marta Di Simone, Miriam Sciortino, Fulvio Brucato, Gianluca Guercio, Miriam Di Caro, Anxur Merenda, Stefania Vasta, Concetta Scazzone, Giulia Bivona, Valentina Calò, Marco Pio La Manna, Nadia Caccamo, Francesco Dieli, Sergio Siragusa, Serena Meraviglia
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260908-000002
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Minimal residual disease (MRD) assessment has emerged as a key prognostic marker in multiple myeloma (MM), with MRD negativity (undetectable MRD, uMRD) correlating with improved progression-free and overall survival. The International Myeloma Working Group recommends standardized protocols for MRD…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Candidate 1
- cancerMultiple Myelomadictionary0.60
Curated evidence
Evidence citing this paper (0)
Data not yet available